Supplementary material

Supplementary methods

To correct for head movement, all images were co-registered to the first M_o map, using a rigid deformation model, with a mono-modal (sum of squared differences) cost function for the later M_o maps. Images were then either co-registered with a mono-modal cost function or a multi-modal (Mattes Mutual Information) metric to the control and label images. Best results were obtained by using the modulus of the spatial gradient of the source images to determine the moving-to-fixed transformation, which was then applied to the source images; this had the effect of guiding the co-registration by emphasising landmarks, without reducing the images entirely to their edges. No brain extraction (skull-stripping) was used or needed. Images were interpolated to uniform voxels in the slice direction before the co-registration step, and downsampled back to the original slice locations immediately afterwards. The final perfusion map was calculated using the single inversion-time formula:

$$f = \frac{\lambda}{2\alpha BL} \frac{\Delta M}{M_{0b}} exp\left(\frac{TI}{T_{1b}}\right)$$

- f Perfusion
- λ Tissue-blood partition coefficient of water
- TI Inversion time
- ΔM The difference signal between control and label images
- M_{0b} Equilibrium magnetization (containing blood spins only)
- T_{1b} The T_1 of blood
- α Inversion fraction
- BL Bolus length

Event
Administration of CBD or placebo
Subjects undergo MRI scanning
Plasma CBD levels taken
Prose Recall (Immediate)
N-Back Task
Prose Recall (Delayed)
Digit Span Task

Supplementary Table 1. Timeline of events, including image acquisition and memory tasks.



Supplementary Figure 1. The relationship between *differences* in blood flow to the orbitofrontal cortex and *differences* in reaction time in the 2-Back task post CBD vs. placebo



Supplementary Figure 2. Plasma CBD levels post-ingestion of 600 mg in CBD vs. placebo sessions. All data points are presented with the mean (\pm standard error of the mean). As demonstrated in this figure, the bioavailability of oral CBD is highly variable between individuals. (** = significant at the p<0.01 level